At a panel at CTO West Coast, experts from biopharmaceutical companies outlined innovative strategies to shape the future of ...

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

Corcept Therapeutics’ relacorilant, a selective glucocorticoid receptor antagonist (SGRA), is emerging as a novel therapeutic ...

OnCusp Therapeutics has reported initial Phase Ia data from its Phase I trial of the CDH6-directed antibody-drug conjugate ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis of Pluvicto.

Arrowhead Pharmaceuticals has dosed the first participant in the Phase I/IIa AROALK7-1001 trial of ARO-ALK7, an ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this population lacking.

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study ...

Diakonos Oncology has closed a $20m private placement of Simple Agreements for Future Equity (SAFE) for its Phase II trial of ...

Johnson & Johnson has reported data from a Phase I trial of pasritamig for metastatic castration-resistant prostate cancer ...

Focus V has shown limited PFS benefit, a high incidence of AEs, and no demonstrated improvement in overall survival.